Prof. dr. E. Eldering

Main activities
Focus of research

The group of Eric Eldering at the Dept of Experimental Immunology of the AMC works on apoptosis regulation in normal and pathological immune cells. We apply cellular, biochemical and molecular biology techniques in human cells and mouse models, in two main research lines. The first concerns translational research into leukemia, driven by clinical problems, in close collaboration with prof Arnon Kater (Dept of Hematology, AMC). We have studied apoptosis (dys)regulation in B cells since 2002, subsequently focusing on Chronic Lymphocytic Leukemia (CLL). We currently study three aspects of CLL biology:
1. CLL functional genetics and molecular diagnostics
2. The leukemic micro-environment, apoptosis dysregulation and novel drugs
3. Interaction between the immune system and CLL with focus on immune metabolism

Second is a research line devoted to more fundamental immunological issues.We have studied the role of Bcl-2 family members in T and B cells during initiation of the immune response. Bcl-2 members Noxa and Mcl-1 control outgrowth of high affinity lymphocytes as well as clonal diversity. Currently we are studying interactions among Bcl-2 family members using a novel technique called BH3 mimetic profiling (Peperzak 2017). The ultimate goal of this research is to apply the insight obtained in novel vaccination and anti-cancer strategies.

In 2014, three NWO Veni laureates have started their own projects: Felix Wensveen studies selection of high affinity T and B cells (finished January 2017), Victor Peperzak investigates regulation of pro-survival Mcl-1 in malignant B cells (moved to UMC Utrecht in Nov 2015), and Rianne van der Windt studies Immunometabolism, which has become an integral part of our Hemato-Oncology research line.

Key publications
  • Pascutti MF, Jak M, Tromp JM, Derks IAM, Remmerswaal EBM, Thijssen R, van Attekum MHA, van Bochove GG, Luijks DM, Pals ST, van Lier RAW, Kater AP, van Oers MHJ, Eldering E, IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. BLOOD 2013;122 (17):3010-3019 [PubMed]
  • Tromp JM, Geest CR, Breij ECW, Elias JA, van Laar J, Luijks DM, Kater AP, Beaumont T, van Oers MHJ, Eldering E, Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia. CLIN CANCER RES 2012;18 (2):487-498 [PubMed]
  • te Raa GD, Derks IAM, Navrkalova V, Skowronska A, Moerland PD, van Laar J, Oldreive C, Monsuur H, Trbusek M, Malcikova J, Lodén M, Geisler CH, Hüllein J, Jethwa A, Zenz T, Pospisilova S, Stankovic T, van Oers MHJ, Kater AP , Eldering E, The impact of SF3B1 mutations in CLL on the DNA-damage response. LEUKEMIA 2015;29 (5):1133-1142 [PubMed]
  • Thijssen R, ter Burg J, Garrick B, van Bochove GGW, Brown JR, Fernandes SM, Rodríguez MS, Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IAM, van Kampen RJW, Hege K, Kersten MJ, Trowe T, Filvaroff EH, Eldering E, Kater AP, Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. BLOOD 2016;128 (4):574-583 [PubMed]
  • Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, van Oers MHJ, Kater AP, Eldering E, Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. HAEMATOLOGICA 2015;100 (8):e302-e306 [PubMed]
All Publications
Research programmes

Apoptosis regulation in immuno-hematology

Themes: Infection and Immunity and Oncology

Prof. dr. E. Eldering
Prof. dr. A.P. Kater MD PhD

Dr. J.M.N. Dubois MD
Dr. S.H. Tonino MD PhD
Dr. G.J.W. van der Windt

PhD Students
Z. Chen PhD
F. Favaro
M.V. Haselager
T. Hofland MSc
K. Kielbassa
A.C. Leeksma MD
C. Montironi
S. Tahri
D. Verhoeven
I. de Weerdt MD

Drs. J. ter Burg
Ing. I.A.M. Derks
D. van Nieuwenhuize
A. Schoonderwoerd

Current research funding
  • AMC
  • Europese Unie
  • Janssen Research & Development, LLC
  • KWF Kankerbestrijding
  • Stichting AMC Foundation (Vrijgesteld)